Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Dominique Xavier Brown, Emma Louise Butler & Marc Evans. (2014) Lixisenatide as add-on therapy to basal insulin. Drug Design, Development and Therapy 8, pages 25-38.
Read now
Read now
John Gerich. (2013) Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. International Journal of General Medicine 6, pages 877-895.
Read now
Read now
Andre Scheen. (2013) Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opinion on Drug Safety 12:4, pages 545-557.
Read now
Read now
André J. Scheen. (2013) Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes. Postgraduate Medicine 125:3, pages 7-20.
Read now
Read now
Denis Raccah. (2013) Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data. Expert Review of Endocrinology & Metabolism 8:2, pages 105-121.
Read now
Read now
Articles from other publishers (21)
Ida Kim Wium‐Andersen, Marie Kim Wium‐Andersen, Anders Fink‐Jensen, Jørgen Rungby, Martin Balslev Jørgensen & Merete Osler. (2022) Use of GLP‐1 receptor agonists and subsequent risk of alcohol‐related events. A nationwide register‐based cohort and self‐controlled case series study. Basic & Clinical Pharmacology & Toxicology 131:5, pages 372-379.
Crossref
Crossref
Xintong Hou, Dan Yang, Guimei Yang, Mengnan Li, Jian Zhang, Jiaxin Zhang, Yi Zhang & Yunfeng Liu. (2022) Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes. Frontiers in Endocrinology 13.
Crossref
Crossref
Juraj Secnik, Hong Xu, Emilia Schwertner, Niklas Hammar, Michael Alvarsson, Bengt Winblad, Maria Eriksdotter, Sara Garcia-Ptacek & Dorota Religa. (2021) The association of antidiabetic medications and Mini-Mental State Examination scores in patients with diabetes and dementia. Alzheimer's Research & Therapy 13:1.
Crossref
Crossref
Anna Veelen, Edmundo Erazo-Tapia, Jan Oscarsson & Patrick Schrauwen. (2021) Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?. Molecular Metabolism 46, pages 101158.
Crossref
Crossref
Katherine A. Lyseng-Williamson. (2019) Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features. Clinical Drug Investigation 39:8, pages 805-819.
Crossref
Crossref
Chan Heo & Chang-Ik Choi. (2019) Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes. Journal of Clinical Medicine 8:3, pages 393.
Crossref
Crossref
Taedong Han, Byoung Moon Lee, Yoo Hoi Park, Dong Hoon Lee, Hyun Ho Choi, Taehoon Lee & Hakwon Kim. (2018) YH18968, a Novel 1,2,4-Triazolone G-Protein Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes Mellitus. Biomolecules & Therapeutics 26:2, pages 201-209.
Crossref
Crossref
Matthew G. Cehic, Nishant Nundall, Jerry R. Greenfield & Peter S. Macdonald. (2018) Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review. Journal of Transplantation 2018, pages 1-14.
Crossref
Crossref
Yoo Hoi Park, Hyun Ho Choi, Dong Hoon Lee, Soo Yong Chung, Na Yeon Yang, Do Hoon Kim, Mi Kyeong Ju, Tae Dong Han, Su Youn Nam & Kyu-Won Kim. (2017) YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse model. Archives of Pharmacal Research 40:6, pages 772-782.
Crossref
Crossref
Fabio Broglio, Edoardo Mannucci, Raffaele Napoli, Antonio Nicolucci, Francesco Purrello, Elena Nikonova, William Stager & Roberto Trevisan. (2017) Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme. Diabetes, Obesity and Metabolism 19:2, pages 248-256.
Crossref
Crossref
Manel Mata‐Cases, Dídac Mauricio & Josep Franch‐Nadal. (2016) Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets. Journal of Diabetes 9:1, pages 34-44.
Crossref
Crossref
R. Sekar, K. Singh, A.W.R. Arokiaraj & B.K.C. Chow. 2016.
279
341
.
Barbara Sottero, Simona Gargiulo, Isabella Russo, Cristina Barale, Giuseppe Poli & Franco Cavalot. (2015) Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies. Medicinal Research Reviews 35:5, pages 968-1031.
Crossref
Crossref
Katsumi Iizuka, Hiroyuki Niwa, Youichi Takahashi & Jun Takeda. (2014) Liraglutide normalised glucose tolerance and the response of insulin to glucose in a non-obese patient with newly diagnosed type-2 diabetes mellitus. Diabetology International 5:4, pages 254-259.
Crossref
Crossref
Mansur Shomali. (2014) Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists. Clinical Diabetes 32:1, pages 32-43.
Crossref
Crossref
André J. Scheen. (2013) GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?. Annales d'Endocrinologie 74:5-6, pages 515-522.
Crossref
Crossref
Timothy S. Reid. (2013) Practical Use of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Primary Care. Clinical Diabetes 31:4, pages 148-157.
Crossref
Crossref
Susan A Cornell. (2013) A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics 38:3, pages 181-189.
Crossref
Crossref
Mary Elizabeth Cox & Mark N. Feinglos. (2013) Risk vs Benefit in Diabetes Pharmacotherapy: a Rational Approach to Choosing Pharmacotherapy in Type 2 Diabetes. Current Diabetes Reports 13:3, pages 319-328.
Crossref
Crossref
Arpita Kalla Vyas, Lauren B. Aerni-Flessner, Maria A. Payne, Attila Kovacs, Patrick Y. Jay & Paul W. Hruz. (2012) Saxagliptin improves glucose tolerance but not survival in a murine model of dilated cardiomyopathy. Cardiovascular Endocrinology 1:4, pages 74-82.
Crossref
Crossref
Dominique Xavier Brown & Marc Evans. (2012) Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective. Journal of Nutrition and Metabolism 2012, pages 1-10.
Crossref
Crossref